To further elucidate the mechanisms of TM on tumor metastasis in patients, a panel of ten collagen/ECM biomarkers were tested in an exploratory cohort, and four (LOXL2, C1M, PRO-C3, and C6M) were identified as being elevated at baseline in those with disease compared with normal controls. This evidence concerns the gene LOXL2 and neoplasm.